Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Augmented hemoperfusion for hyperbilirubinemia.

B F Brian1, W J Dorson, V B Pizziconi

  • 1Department of Chemical, Bio and Materials Engineering, Arizona State University, Tempe 85287.

ASAIO Transactions
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovative surgical treatment of persistent unilesional breast mycosis fungoides by mastopexy.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2014
Same author

Factors associated with symptom-specific psychological and functional impact among acoustic neuroma patients.

The Journal of laryngology and otology·2013
Same author

Factors associated with anxiety and depression in the management of acoustic neuroma patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2011
Same author

Crystallization kinetics of sol-gel derived hydroxyapatite thin films.

Journal of materials science. Materials in medicine·2004
Same author

A cell-based immunobiosensor with engineered molecular recognition--Part I: Design feasibility.

Biosensors & bioelectronics·1997
Same author

A cell-based immunobiosensor with engineered molecular recognition--Part II: Enzyme amplification systems.

Biosensors & bioelectronics·1997
Same journal

Extracorporeal membrane oxygenation as a means of stabilizing and transporting high risk neonates.

ASAIO transactions·1991
Same journal

Pumping capabilities of the latissimus dorsi and rectus abdominis muscles wrapped around a valved pouch in a mock circulatory system.

ASAIO transactions·1991
Same journal

Causes of intraaortic balloon leaks.

ASAIO transactions·1991
Same journal

Influence of centrifugal blood pumps on the elasticity of erythrocytes.

ASAIO transactions·1991
Same journal

Reuse of "highly permeable" dialyzers with peroxyacetic acid as sole cleansing and disinfecting agent.

ASAIO transactions·1991
Same journal

Comparison of 50% dextrose water, 25% mannitol, and 23.5% saline for the treatment of hemodialysis-associated muscle cramps.

ASAIO transactions·1991
See all related articles

Sodium benzoate enhances hemoperfusion treatment for hyperbilirubinemia by improving bilirubin removal rates. This biocompatible agent significantly boosts the effectiveness of coated activated charcoal in blood purification.

Area of Science:

  • Biomedical Engineering
  • Clinical Chemistry
  • Hematology

Background:

  • Hyperbilirubinemia is treated with exchange transfusions and phototherapy, but these methods have limitations.
  • Hemoperfusion using coated activated charcoal (CAC) shows low bilirubin removal due to strong albumin binding.
  • Novel biocompatible agents are needed to improve bilirubin detachment for enhanced hemoperfusion efficacy.

Purpose of the Study:

  • To investigate biocompatible chemical agents for selectively unbinding bilirubin prior to hemoperfusion.
  • To assess the efficacy of sodium benzoate in augmenting bilirubin removal by CAC.
  • To evaluate the impact of sodium benzoate on hemoperfusion performance in plasma and blood.

Main Methods:

  • Batch and flow tests were conducted using mock solutions, human plasma, and bovine plasma/blood.

Related Experiment Videos

  • Coated activated charcoal (CAC) was used as the adsorbent.
  • Sodium benzoate was added at varying concentrations (50 mM and 100 mM) to assess its effect on bilirubin removal.
  • Platelet aggregation was measured to evaluate biocompatibility.

    • Main Results:

    • Sodium benzoate significantly increased bilirubin removal, reaching 96% at 100 mM in mock solutions.
    • Pretreatment of CAC with sodium benzoate was necessary due to rapid adsorptive removal.
    • In plasma and blood, 100 mM sodium benzoate increased bilirubin removal by 25% (plasma) and 35% (blood).
    • A notable decrease in platelet aggregation was observed with sodium benzoate addition.

    Conclusions:

    • Sodium benzoate effectively enhances bilirubin removal during hemoperfusion with CAC.
    • This augmented hemoperfusion shows promise as a clinically attractive treatment for hyperbilirubinemia.
    • The reduction in platelet aggregation further supports the potential clinical utility of this method.